EUVIMEDEUVIMED entdecken
Crossref

Prevalence and Clinical Characteristics of Germline Epidermal Growth Factor Receptor Mutations in the Southeastern United States

Jenny O'Brien iD, Ryne C Ramaker iD, Ashley Moyer iD, John H Strickler iD, Betty C Tong, Megan E Ramaker iD, Svati H Shah, Laura Alder iD, Thomas E Stinchcombe iD, Jeffrey M Clarke

JCO Precision Oncology · 2026

DOI: 10.1200/po-25-00678 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2026. Verfasst von Jenny O'Brien und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Medicine, Duke University, Durham, NC. Hauptthemen laut MEDLINE: Germ-Line Mutation, ErbB Receptors, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung. Die Arbeit nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Up to 1% of patients with non–small cell lung cancer harbor germline epidermal growth factor receptor ( EGFR ) mutations, although they remain poorly described in unselected, noncancer populations. We sought to characterize the prevalence of germline EGFR mutations in Southeastern United States. METHODS We assessed the prevalence of EGFR mutations in unselected cohorts of individuals enrolled in the Duke CATHeterization GENetics, gnomAD, UK Biobank, and All of Us studies. We additionally performed comprehensive chart review for patients evaluated at the Duke Cancer Institute with germline EGFR mutations. RESULTS We found the prevalence of germline EGFR T790M to be >1 in 3,000 individuals in the Duke catchment area. This prevalence was 7.5 times greater than the national All of Us cohort, 3.7 times greater than the international gnomAD cohort, and 55.8 times greater than the UK Biobank cohort. The Southeastern region also contained the highest proportion of T790M carriers in the All of Us cohort. Twenty-eight individuals with suspected germline EGFR mutations were identified in our institutional cohort. The majority of these patients did not have a history of smoking, had multiple lung nodules at the time of diagnosis, and had a family history of cancer. Forty-five percent of patients had a diagnosis of a second primary malignancy. CONCLUSION Our analysis represents the largest study to date assessing the prevalence of germline EGFR mutations from both patients with lung cancer and unselected cohorts of individuals and presents evidence for increased prevalence of EGFR T790M mutations within the Southeastern United States. Given the high prevalence and documented hereditary risk of germline EGFR mutations, future studies investigating the role of familial testing and screening in these individuals is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Germ-Line MutationErbB ReceptorsLung NeoplasmsCarcinoma, Non-Small-Cell LungHumansFemalePrevalenceMaleSoutheastern United StatesMiddle AgedAgedCohort Studies

Substanzen

ErbB ReceptorsEGFR protein, human

Autor:innen und Institutionen

  • Division of Medical Oncology, Department of Medicine, Duke University, Durham, NC.
  • Department of Pathology, Duke University, Durham, NC.
  • Division of Cardiovascular and Thoracic Surgery, Department of Surgery, Duke University, Durham, NC.
  • Center for Precision Health, Duke Clinical and Translational Science Institute, Duke University, Durham, NC.

ORCID-Profile: Jenny O'Brien, Ryne C Ramaker, Ashley Moyer, John H Strickler, Megan E Ramaker, Laura Alder, Thomas E Stinchcombe

Zitieren

APA

O'Brien, J., Ramaker, R. C., Moyer, A., Strickler, J. H., Tong, B. C., Ramaker, M. E., Shah, S. H., Alder, L., Stinchcombe, T. E., & Clarke, J. M. (2026). Prevalence and Clinical Characteristics of Germline Epidermal Growth Factor Receptor Mutations in the Southeastern United States. JCO Precision Oncology. https://doi.org/10.1200/po-25-00678

Vancouver

O'Brien J, Ramaker RC, Moyer A, Strickler JH, Tong BC, Ramaker ME, et al. Prevalence and Clinical Characteristics of Germline Epidermal Growth Factor Receptor Mutations in the Southeastern United States. JCO Precision Oncology. 2026. doi:10.1200/po-25-00678

BibTeX
@article{OBrien2026,
  author = {O'Brien, Jenny and Ramaker, Ryne C and Moyer, Ashley and Strickler, John H and Tong, Betty C and Ramaker, Megan E and Shah, Svati H and Alder, Laura and Stinchcombe, Thomas E and Clarke, Jeffrey M},
  title = {Prevalence and Clinical Characteristics of Germline Epidermal Growth Factor Receptor Mutations in the Southeastern United States},
  journal = {JCO Precision Oncology},
  year = {2026},
  doi = {10.1200/po-25-00678}
}
Kostenlos starten →